Squarepoint Ops LLC Makes New Investment in Cellectar Biosciences, Inc. (NASDAQ:CLRB)

Squarepoint Ops LLC acquired a new stake in shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 520,240 shares of the biopharmaceutical company’s stock, valued at approximately $156,000. Squarepoint Ops LLC owned approximately 1.13% of Cellectar Biosciences as of its most recent SEC filing.

Separately, JPMorgan Chase & Co. lifted its holdings in shares of Cellectar Biosciences by 687.3% in the 4th quarter. JPMorgan Chase & Co. now owns 182,403 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 159,234 shares during the last quarter. 16.41% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on CLRB shares. Maxim Group reaffirmed a “hold” rating on shares of Cellectar Biosciences in a report on Wednesday, May 14th. Wall Street Zen initiated coverage on shares of Cellectar Biosciences in a research note on Wednesday, May 21st. They set a “sell” rating for the company.

Cellectar Biosciences Stock Down 11.6%

Shares of CLRB stock opened at $0.36 on Monday. The firm has a market cap of $16.63 million, a price-to-earnings ratio of -0.21 and a beta of 0.52. The company’s 50 day moving average is $0.28 and its 200 day moving average is $0.40. Cellectar Biosciences, Inc. has a 52-week low of $0.22 and a 52-week high of $3.42.

Cellectar Biosciences (NASDAQ:CLRB) last issued its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.04. Analysts anticipate that Cellectar Biosciences, Inc. will post -1.59 EPS for the current fiscal year.

About Cellectar Biosciences

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.